RLAY Relay Therapeutics, Inc.

NASDAQ
$18.87

Relay Therapeutics, Inc. (RLAY) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal Bearish Selling ran elevated versus RLAY's own trailing one-year pace, with 2% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 5 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
5
6 transactions
Purchases
$0
0 shares
Sales
$118.9M
6,127,153 shares
Net activity
-$118.9M
purchases less sales

How much of that selling was preplanned? 2% planned / 98% discretionary

10b5-1 plan sales $2.5M 5 transactions · 127,153 shares
Discretionary sales $116.4M 1 transaction · 6,000,000 shares

Largest single sale: $116.4M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Patel Sanjiv President and CEO Sell 10b5-1 48,199 $18.94 $912.9K 519,500 −8.5% of holding
Catinazzo Thomas Chief Financial Officer Sell 10b5-1 17,717 $18.94 $335.6K 122,851 −12.6% of holding
Bergstrom Donald A President, R&D Sell 10b5-1 8,530 $18.97 $161.8K 399,130 −2.1% of holding
Rahmer Peter See remarks Sell 10b5-1 4,508 $20.03 $90.3K 223,657 −2% of holding
Sell 6,000,000 $19.40 $116.4M 21,904,963 −21.5% of holding
Patel Sanjiv President and CEO Sell 10b5-1 48,199 $20.33 $979.9K 567,699 −7.8% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.